Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Exploratory Analysis of Biomarkers and Treatment Outcomes from the COLUMBUS Study in BRAF V600E/K-Mutant Advanced or Metastatic Melanoma.

Clinical cancer research : an official journal of the American Association for Cancer Research - 1 Apr 2026

Dummer Reinhard, Deng Shibing, Xie Tao, Pathan Nuzhat, Saffari Hedieh, Robert Caroline, Arance Ana, de Groot Jan Willem B, Garbe Claus, Gogas Helen J, Gutzmer Ralf, Krajsová Ivana, Liszkay Gabriella, Loquai Carmen, Mandala Mario, Schadendorf Dirk, Yamazaki Naoya, Ascierto Paolo A, Davis Craig B, Shah Khyati, Hamilton Phineas, di Pietro Alessandra, Flaherty Keith

Abstract excerpt

PURPOSE: Treatment with encorafenib ± binimetinib is associated with improved survival versus vemurafenib in patients with BRAF V600E/K-mutant advanced melanoma. We retrospectively analyzed genomic and transcriptomic data from the phase III COLUMBUS trial to identify molecular correlates of benefit with encorafenib ± binimetinib. EXPERIMENTAL DESIGN: In COLUMBUS, patients with BRAF V600E/K-mutant locally...

Topics

Join the communities discussing this publication.

Antineoplastic Combined Chemotherapy Protocols
Benzimidazoles
Carbamates

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Exome Sequencing

Neoplasm Metastasis

Source

Open in PubMed Open full text

Identifiers

PMID: 41537702
DOI: 10.1158/1078-0432.CCR-25-3262
PMCID: PMC13040209

Genes

BRAF

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Exploratory Analysis of Biomarkers and Treatment Outcomes from the COLUMBUS Study in BRAF V600E/K-Mutant Advanced or Metastatic Melanoma.PMID 41537702Read ↗

COLUMBUS 7-year update: A randomized, open-label, phase III trial of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF V600E/K-mutant melanoma.Semantic proximity Read ↗

COLUMBUS 5-Year Update: A Randomized, Open-Label, Phase III Trial of Encorafenib Plus Binimetinib Versus Vemurafenib or Encorafenib in Patients With BRAF V600-Mutant Melanoma.Semantic proximity Read ↗

Update on tolerability and overall survival in COLUMBUS: landmark analysis of a randomised phase 3 trial of encorafenib plus binimetinib vs vemurafenib or encorafenib in patients with BRAF V600-mutant melanoma.Semantic proximity Read ↗

Molecular profiling of BRAF-V600E-mutant metastatic colorectal cancer in the phase 3 BEACON CRC trial.Semantic proximity Read ↗

Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial.Semantic proximity Read ↗

Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial.Semantic proximity Read ↗

Longitudinal Genomic Analysis to Fine-tune Targeted Therapy: Results of the Phase II LOGIC 2 Trial in Patients with BRAFV600-Mutant Metastatic Melanoma.Semantic proximity Read ↗

COLUMBUS 5-year update: a randomized, open-label, phase III trial of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF.Semantic proximity Read ↗

COLUMBUS-AD: phase III study of adjuvant encorafenib + binimetinib in resected stage IIB/IIC BRAF V600-mutated melanoma.Semantic proximity Read ↗

STARBOARD: encorafenib + binimetinib + pembrolizumab for first-line metastatic/unresectable BRAF V600-mutant melanoma.Semantic proximity Read ↗

primary analysis of the RANDOMIZED eortc-2139/columbus-ad trial: Adjuvant encorafenib and binimetinib versus placebo in high-risk stage II BRAF-V600E/K melanoma.Semantic proximity Read ↗

Biomarker study of pembrolizumab in patients with advanced rare cancers.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.